Newrotex is a UK-based biotech firm using silk biomaterials to create medical solutions for the nervous system. A firm eligible for Knowledge-Intensive EIS funding, our first product…
While our inaugural biomedical application is focused on peripheral nerve injuries (PNI), our future verticals include central nervous system (CNS) repair, organoids for testing CNS pharmaceuticals, and drug/growth factor delivery vehicles.
Read Our Solution page for more details on our luminal silk fibres and silk conduits.
The first Newrotex solution is a simple off-the-shelf product set to disrupt the standard approaches to peripheral nerve injuries. Our patented luminal silk fibres are in first-in-human trials with safety data due in Q1 of 2026. Following that, Newrotex will seek to carry out a market approval study in the USA and the UK in order to progress towards market approval.
Headquartered in the research-rich “Golden Triangle” of UK universities in Oxford, Cambridge, and London. Newrotex maintains deep connections with the academic community, while establishing strong relationships in the area’s innovative commercial sector.
Our offices, laboratory, and manufacturing space are located in the Wood Centre for Innovation, Oxford, a thriving nexus where science, technology, and business converge.
By taking full advantage of our own manufacturing facilities, we have established high quality manufacturing standards and processes which has resulted in us achieving ISO 13485 certification to manufacture for human use.
A trauma and orthopaedic surgeon, Dr Woods has extensive experience in silk technology and medical devices. He holds a D.Phil in Zoology and a Bachelor of Medicine, Bachelor of Surgery from Oxford University.
Katie Slater worked as a transactional lawyer before transitioning to a career in commercial operations. She has experience in large organisations managing operational transformations to drive commercial performance.
Adele has over 25 years’ experience in the biotech, medical devices and in vitro diagnostic industries. She has held senior roles across Production, Quality and Regulatory Affairs at both large international and small start-up companies such as Lonza Biologics, Wellcome (GSK), Genzyme, Chemicon (Merck), Scapa Healthcare and Oxford Medical Products. She has also worked as a IRCA certified QMS Medical Directives Lead Auditor for over 10 years, assessing quality systems to ISO 9001 and ISO 13485 and technical documentation to international regulatory requirements on behalf of LRQA and BSI.
Harsh is a biotechnologist with a Master’s degree from Nottingham Trent university. He joins us as a Laboratory Technician where he is currently advancing our nerve repair solutions.
Chris holds a Ph.D. in Biochemistry and Biotechnology and has over a decade of experience converting innovation from research status into commercial products.
Jessica joined Newrotex in the summer of 2022 with 5 years proven laboratory experience working to GLP, MHRA and ISO standards. She has experience in biomedical laboratories leading day-to-day operations, developing assays, troubleshooting laboratory processes and implementing internal quality assurance.
Sharon is a qualified AAT bookkeeper and has a professional diploma in Accounting. She has worked with Startup companies in finance since 2016.
Chris Jones has been a Director of Becton Dickinson since 2010, holding a seat on the board’s Executive Committee. He served as the Board Chair at Cello Health until its acquisition in Aug 2020, is a trustee of the Lasker Foundation, and has been on the Health Advisory Board at Johns Hopkins Bloomberg School of Public Health since 1997.
Professor Vollrath leads the Oxford Silk Group at the University of Oxford and has experience as the founder and director of several start-ups, including Oxford Biomaterials and Newrotex. He holds an MSc in Neurobiology and has extensive expertise with silk and silk-based devices.
Lucy Woods is an experienced CEO, having managed businesses with substantial turnaround requirements for the past 16 years. She was named an EY Entrepreneur of the Year in 2020.
James Mallinson has over 25 years of experience as a VC advisor, both at the seed and later stages. He managed the University of Oxford’s technology spinout portfolio for 15 years, eventually as Director of Oxford Spinout Equity Management.
For more information or to discuss partnership opportunities with Newrotex, please contact info@newrotex.com.
